Recombinant lipase (Mayoly-Spindler/AzurRx BioPharma)

Phase II Active

A yeast-derived recombinant lipase potentially for the treatment of pancreatitis.

Research Code MS-1819; MS-1819-SD 

CAS No.

Thrombin topical

(Recothrom^®) Approved

A recombinant thrombin used to aid hemostasis and control non-arterial bleeding during surgical procedures.

Research Code

CAS No. 9002-04-4

Recombinant human cathepsin L (Halozyme Therapeutics)

Phase II Active

A recombinant human cathepsin-L potentially for treatment of cellulite.

Research Code HTI-501; rHuCAT-L

CAS No.

Rasburicase biosimilar (Virchow Group)

(Tuly^®) Active

A recombinant urate oxidase potentially for the prevention and treatment of malignancy-associated hyperuricaemia.

Research Code

CAS No. 134774-45-1 (Rasburicase)

Nateplase

(Milyzer, Tepase^®) Approved

A recombinant single-chain human tissue-type plasminogen activator used to treat myocardial infarction.

Research Code MMR-701

CAS No. 159445-63-3

Agalsidase beta biosimilar (JCR Pharmaceuticals/GlaxoSmithKline)

Phase III Active

A recombinant alfa-galactosidase potentially for the treatment of Fabry's disease.

Research Code JR-051

CAS No. 104138-64-9 (Agalsidase beta)

Recombinant alkaline phosphatase (AM-Pharma)

Phase II Active

A recombinant alkaline phosphatase potentially for the treatment of hypophosphatasia and acute renal failure.

Research Code recAP

CAS No. 9001-78-9

EZN-2279

Phase III Active

A polyethylene glycol recombinant adenosine deaminase (ADA) potentially for the treatment of adenosine deaminase deficiency in patients with severe combined immunodeficiency disease (SCID).

Research Code EZN-2279; STM-279; rhADA; PEG-rADA

CAS No. 9026-93-1 (Adenosine deaminase)

Lesinidase alfa

Phase II Active

A recombinant human NaGlu potentially for the treatment of mucopolysaccharidosis IIIB.

Research Code SBC-103; rhNaGlu; 61A4G0P3IB

CAS No. 1802497-18-2

Lecithin-modified superoxide dismutase

Phase II Active

A superoxide dismutase analogue potentailly for the treatment of interstitial lung diseases and ulcerative colitis.

Research Code LT-0011; PCSOD; PCSOD-NE

CAS No.

SHP-610

Phase II Active

A recombinant human heparan N-sulfatase potentially for the treatment of mucopolysaccharidosis IIIA (MPS IIIA/Sanfilippo syndrome type A).

Research Code SHP-610; HGT-1410

CAS No.

MEDI-6012

Phase II Active

A recombinant human lecithin-cholesterol acyltransferase (LCAT) potentially for the treatment of acute coronary syndrome (ACS) and coronary artery disease (CAD).

Research Code ACP-501; MEDI-6012; rhLCAT

CAS No.

GSK-2586881

Phase II Active

A recombinant angiotensin converting enzyme-2 (rhACE2) potentially for the treatment of acute lung injury and respiratory distress syndrome.

Research Code APN-01; GSK-2586881; rhACE2; 2586881

CAS No.

PEG-GC

(Lysodase^®) Phase I Discontinued

A pegylated glucocerebrosidase potentially for the treatment of Gaucher's disease.

Research Code PEG-GC; PEG-rGC; PEG-rGCS

CAS No.

Reveglucosidase alfa

Phase III Discontinued

A fusion protein of insulin-like growth factor 2 (IGF-2) and α-glucosidase (GAA) used to treat Pompe disease (GAA deficiency).

Research Code GILT-rhGAA ; BMN-701; ZC-701; IGF2-GAA; E86R97M8XQ (UNII code)

CAS No. 1446198-96-4

Imiglucerase biosimilar (International Biotech Center Generium)

Phase I Active

A recombinant glucocerebrosidase potentially for the treatment of type I Gaucher's disease.

Research Code GNR-008

CAS No. 154248-97-2 (Imiglucerase)

Superoxide dismutase liposomal (Apeiron Biologics)

(Lipoxysan^®) Phase III Pending

A liposomal formulation of recombinant human Cu/Zn superoxide dismutase potentially for the treatment of Peyronie's disease.

Research Code APN-201

CAS No. 9054-89-1

Alpha-1 antitrypsin (Kamada)

(Glassia^®) Approved

A human antitrypsin used to treat alpha 1-antitrypsin deficiency.

Research Code AAT-IH; AAT-IV; Inhaled-AAT; IV AAT

CAS No. 480637-44-3

Olipudase alfa

Phase III Active

A recombinant human acid sphingomyelinase (rhASM) potentially for the treatment of Niemann-pick disease.

Research Code GZ-402665; rhASM

CAS No. 927883-84-9

GNR-004

(Reveliza^®) Phase III Active

A recombinant tissue plasminogen activator potentially for the treatment of myocardial infarction.

Research Code GNR-004

CAS No.